Iclusig (ponatinib)

About Angelini Pharma

Angelini Pharma is a century-old, private Italian pharmaceutical company with a significant international commercial footprint across Europe and the United States. Its strategy is built on a diversified portfolio spanning prescription drugs in Brain Health, Specialty Care, and over-the-counter Consumer Healthcare products. The company demonstrates a clear commitment to its core therapeutic areas through ongoing commercial initiatives, medical education platforms like Headway, and a pipeline that includes recently launched CNS products such as Ontozry.

About Incyte

Incyte is a publicly traded, revenue-generating biopharmaceutical company with a market valuation of approximately $18.19 billion, built on a foundation of targeted small molecule science. Its commercial success is anchored by Jakafi® (ruxolitinib) in myelofibrosis and polycythemia vera, with a diversified pipeline extending into oncology and immunology. The company's strategy combines internal R&D excellence with strategic partnerships to expand its therapeutic footprint and commercial reach globally.

Therapeutic Areas